{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:37:55Z","timestamp":1789382275534,"version":"build-2803163510"},"reference-count":96,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.trecan.2025.01.005","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:49:49Z","timestamp":1738277389000},"page":"245-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"Sarah","family":"Waliany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin F.","family":"Gainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2025.01.005_bb0005","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.trecan.2025.01.005_bb0010","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.01.005_bb0020","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0025","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung","volume":"30","author":"Han","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0035","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0040","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0050","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0055","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0060","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006802","article-title":"A genomics-based classification of human lung tumors","volume":"5","author":"The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM)","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0070","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0075","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0090","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0095","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","article-title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"36","author":"Mok","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0100","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S1470-2045(14)70452-8","article-title":"Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009), a randomised, double-blind, phase 3 trial","volume":"15","author":"Ramalingam","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0105","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0110","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0115","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0120","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0125","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of Phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0130","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2025.01.005_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0140","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.01.005_bb0145","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0150","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2025.01.005_bb0155","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2025.01.005_bb0160","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2025.01.005_bb0165","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.01.005_bb0170","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.01.005_bb0175","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0180","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0185","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2020.03.009","article-title":"Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)","volume":"143","author":"Eide","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.trecan.2025.01.005_bb0190","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.01.005_bb0195","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40265-020-01441-6","article-title":"Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"81","author":"Mok","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.trecan.2025.01.005_bb0200","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.01.005_bb0205","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0210","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0215","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtho.2019.11.004","article-title":"Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the Phase 2 ALTA trial","volume":"15","author":"Huber","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0220","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.jtho.2024.09.361","article-title":"Mechanisms of resistance to first-line vs later-line alectinib in ALK fusion-positive NSCLC","volume":"19","author":"Waliany","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0225","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0230","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0235","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2025.01.005_bb0240","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0245","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0250","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.annonc.2021.02.012","article-title":"Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs","volume":"32","author":"Felip","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0255","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.01.005_bb0260","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","article-title":"Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer","volume":"3","author":"Shiba-Ishii","year":"2022","journal-title":"Nat. Cancer."},{"key":"10.1016\/j.trecan.2025.01.005_bb0265","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0270","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/oncolo\/oyae205","article-title":"Advances and future directions in ROS1 fusion-positive lung cancer","volume":"29","author":"Boulanger","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.trecan.2025.01.005_bb0275","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0280","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.trecan.2025.01.005_bb0285","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung Cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0290","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-22-0968","article-title":"NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.01.005_bb0295","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.24.00731","article-title":"Efficacy and safety of taletrectinib in chinese patients with ROS1+ non-small cell lung cancer: the Phase II TRUST-I Study","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0300","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.trecan.2025.01.005_bb0305","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1078-0432.CCR-10-1934","article-title":"Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation","volume":"17","author":"Elmeliegy","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.01.005_bb0310","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.lungcan.2013.08.013","article-title":"Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis","volume":"82","author":"Chen","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.trecan.2025.01.005_bb0315","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood\u2013brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.01.005_bb0320","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR -mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0325","article-title":"Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non\u2013small-cell lung cancer","volume":"2017","author":"Gainor","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0330","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0335","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1200\/JCO.2015.63.5888","article-title":"Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014","volume":"34","author":"Solomon","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0340","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0345","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0350","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0355","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 Phase I\/II Trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0360","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0365","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","volume":"29","author":"Cho","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0370","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0375","article-title":"Amivantamab and lazertinib in treatment-naive EGFR-mutated advanced non-small-cell lung cancer (NSCLC): long-term follow-up and ctDNA results from CHRYSALIS","volume":"41","author":"Lee","year":"2023","journal-title":"J. Clin Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0380","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR -mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0385","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.01.005_bb0390","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0395","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0400","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8509","article-title":"KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced\/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation","volume":"42","author":"Mok","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0405","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"De Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2025.01.005_bb0410","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0415","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153470","article-title":"Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47","volume":"133","author":"Hu","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2025.01.005_bb0420","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm8780","article-title":"Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers","volume":"8","author":"Mugarza","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.trecan.2025.01.005_bb0425","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jtho.2022.07.025","article-title":"OA03.06 CodeBreaK 100\/101: first report of safety\/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC","volume":"17","author":"Li","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0430","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2023.10.066","article-title":"LBA65\u2013KRYSTAL-7: efficacy and safety of adagrasib with pembrolizumab in patients with treatment-na\u00efve, advanced non-small-cell lung cancer (NSCLC) harboring a KRASG12C mutation","volume":"34","author":"Garassino","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0435","doi-asserted-by":"crossref","first-page":"8510","DOI":"10.1200\/JCO.2024.42.16_suppl.8510","article-title":"Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC","volume":"42","author":"Burns","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0440","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0445","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRAS G12C Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.01.005_bb0450","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.01.005_bb0455","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2024.42.16_suppl.3008","article-title":"Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors","volume":"42","author":"Zhao","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0460","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8511","article-title":"KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC","volume":"42","author":"Gregorc","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0465","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.01.005_bb0470","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-24-0374","article-title":"Unlocking the next frontier in precision oncology: addressing drug-tolerant residual disease","volume":"14","author":"Lin","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.01.005_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109681","article-title":"EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV non-small cell lung cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study","volume":"184","author":"Peng","year":"2023","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.trecan.2025.01.005_bb0480","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-22-3146","article-title":"Early clearance of plasma epidermal growth factor receptor mutations as a predictor of outcome on osimertinib in advanced non-small cell lung cancer; exploratory analysis from AURA3 and FLAURA","volume":"29","author":"Gray","year":"2023","journal-title":"Clin. Cancer Res."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325000068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325000068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T15:30:52Z","timestamp":1741707052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803325000068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2405803325000068"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2025.01.005","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2025.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}